Median length of orphan and non-orphan drugs in phase III trial 2015
This statistic displays the median length of time that orphan and non-orphan products are in phase III trial, as of 2015. Orphan drugs were in phase III trials for a median of 2.89 years. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
